|Dr. John A. Scarlett||CEO, Pres & Chairman||1.39M||N/A||1951|
|Ms. Olivia Kyusuk Bloom||Exec. VP of Fin., CFO & Treasurer||761.54k||N/A||1969|
|Dr. Andrew J. Grethlein||Exec. VP & COO||791.52k||N/A||1964|
|Ms. Melissa A. Kelly Behrs||Exec. VP of Bus. Operations & Chief Alliance Officer||764.81k||N/A||1964|
|Dr. Aleksandra Rizo M.D., Ph.D.||Exec. VP & Chief Medical Officer||892.29k||N/A||1975|
|Ms. Suzanne Messere||Head of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Stephen N. Rosenfield||Exec. VP, Chief Legal Officer & Corp. Sec.||N/A||N/A||1950|
|Ms. Shannon Odam||VP of HR||N/A||N/A||N/A|
|Mr. Anil Kapur||Chief Commercial Officer & Exec. VP of Corp. Strategy||N/A||N/A||1970|
|Mr. Edward E. Koval||Exec. VP & Chief Bus. Officer||N/A||N/A||1962|
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 8; Compensation: 7.